Futura Medical PLC (AIM:FUM, OTC:FAMDF) provided keen investors with further details about the US launch plans for its fast-acting gel for erectile dysfunction from blue-chip partner Haleon PLC.
The AIM-listed healthcare company said since yesterday, 1 September, Eroxon is now available for pre-order online for delivery next month.
It will be available in stores in the US in October, it added.
Futura shares leapt 18.5% higher to 39.7p in morning trading.
Eroxon is the first US Food & Drug Administration-approved topical erectile dysfunction treatment for sale over-the-counter.
Futura out-licensed US rights to Haleon following FDA approval in July 2023, with Futura receiving undisclosed royalties on in-market sales and commercial milestones.
Broker Stifel said it is currently assuming a £4 million US launch milestone in 2025, but bringing this forward to 2024 would see Futura report its first profit this year.
** Update: Adds share price and broker comment **